UnitedHealth Group Incorporated (UNH) shares climbed 2.8% on Friday, closing at $379.98 and marking a third consecutive session in positive territory. The rally came as traders returned to U.S. health insurers amid growing signs that medical-cost pressures may be easing. UNH significantly outperformed the broader market, with the S&P 500 rising just 0.84% on the day.
This upward move has captured Wall Street's attention as analysts assess whether the largest U.S. health insurer is moving beyond a period of repair and beginning a sustainable rebound. The positive sentiment was bolstered by CVS Health's upward revision of its 2026 profit outlook earlier this week, driven by tighter cost management at its Aetna unit. Molina Healthcare also outlined a longer-term profit target, contingent on stable claims expenses.
UnitedHealth's first-quarter results provided a solid foundation for the rally. The company reported revenue of $111.7 billion, with earnings per share of $6.90 and adjusted earnings of $7.23. Management raised its full-year adjusted earnings forecast to above $18.25 per share. CEO Stephen Hemsley stated that the company aims to deliver “greater value, affordability, transparency and connectivity.”
Beyond the numbers, UnitedHealthcare announced plans to eliminate prior authorization requirements for 30% of services currently requiring insurer approval. The changes will target select outpatient surgeries, certain diagnostic tests such as echocardiograms, some therapies, and chiropractic care, with implementation expected by the end of 2026. UnitedHealthcare chief Tim Noel emphasized that prior authorization should only apply when it “truly protects patients and improves care,” noting that the process currently affects just 2% of its medical services, with roughly 92% of requests approved within 24 hours.
The broader sector also saw strong gains. Humana surged 11.3%, CVS Health rose 3.7%, and Elevance Health added 1.3%. Both Humana and CVS have significant exposure to Medicare Advantage plans, which serve older adults and some individuals with disabilities.
However, the outlook is not without risks. Medical expenses could rise if seniors require more care, and CVS's CFO flagged that the 2027 Medicare Advantage payment increase from the U.S. government still falls short of projected cost growth. UnitedHealth's latest quarterly report also highlighted the unpredictability of legal and regulatory expenses, including ongoing responses to subpoenas and government investigations related to Medicare risk-adjustment coding. An unfavorable outcome there, or an uptick in care demand, could threaten the pace of margin recovery.
For now, UnitedHealth has lifted its outlook, trimmed administrative hurdles, and received a boost from peer results. The key test lies ahead: claims trends in the second and third quarters will need to align with the optimistic narrative that investors are currently pricing in.
